Intrapleural fibrinolytic therapy for empyema and pleural loculation: knowns and unknowns
Main Authors: | Idell, S, Rahman, N |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Thoracic Society
2018
|
Similar Items
-
Precision-guided, personalized intrapleural fibrinolytic therapy for empyema and complicated parapneumonic pleural effusions: The case for the fibrinolytic potential
by: Idell, S, et al.
Published: (2017) -
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models
by: Komissarov, A, et al.
Published: (2016) -
Intrapleural agents for pleural infection: fibrinolytics and beyond.
by: Rahman, N
Published: (2012) -
Intrapleural and plasma processing of LTI-01 (single chain urokinase Plasminogen Activator, scuPA) in a phase 1b trial of LTI-01 Intrapleural Fibrinolytic Therapy (IPFT) in patients with Complicated Parapneumonic Effusions (CPE) or empyema
by: Komissarov, A, et al.
Published: (2019) -
Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
by: Idell, S, et al.
Published: (2019)